Oncolysin B

Drug Profile

Oncolysin B

Alternative Names: Anti-B4-bR; Anti-CD19-bR; B4 blocked ricin

Latest Information Update: 08 Nov 1999

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImmunoGen
  • Developer ImmunoGen; Massachusetts General Hospital; Nonindustrial source
  • Class Immunotoxins; Monoclonal antibodies
  • Mechanism of Action CD19 antigen inhibitors; Immunosuppressants; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Leukaemia; Lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 08 Nov 1999 A phase II study has been added to the therapeutic trials and pharmacodynamics sections
  • 02 Sep 1998 A study has been added to the therapeutic trials section
  • 20 Mar 1997 Discontinued-II for Leukaemia in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top